Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

Dr. Jacob Sands explained that he believes patients should be having more personalized, nuanced conversations with their ...